Liquid Segment has the Largest Share of State of Finished Products in the Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market during 2021–2028

According to our latest study on “Asia Pacific Pharmaceutical Fill and Finish Outsourcing Market Forecast to 2028 – COVID-19 Impact and Analysis – by State of Finished Products, and Content,” the market is projected to reach US$ 691.8 million by 2028 from US$ 410.0 million in 2021; it is expected to grow at a CAGR of 7.8% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars. However, complex processes and high cost of production critically impacts the growth of the market.

The COVID-19 pandemic has brought unprecedented challenges globally. Similar effects were witnessed on Asia-Pacific Biopharmaceutical industry that has been disturbed for few months of 2020 during the outbreak of the COVID-19 pandemic. However, with the rising demand for products to treat the COVID-19 infection, the biopharmaceutical and pharmaceutical companies in the countries such as India and China have increased their production of APIs as the countries are the largest exporters to western companies. For instance, Wockhardt Ltd is in talks with the Indian government to offer its fill-finish capacity for the covid-19 vaccines that will be developed in the country, as well as with some firms whose vaccines are currently in phase I/II trials globally. Moreover, on 07 May 2020, Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services with sites in Belgium, United States, Japan, and India, announced it has entered into a manufacturing services agreement with CytoDyn Inc., a late-stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for Mild-to-Moderately Ill and Severely Ill COVID-19 patients.

Based on state of finished products, the liquid segment is expected to register the largest market share during the forecast period. Moreover, the same segment is estimated to register the highest CAGR during the forecast period. In 2021, the liquid segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 6.0% in the forecast period.

Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, MabPlex International Ltd, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., WOCKHARDT, Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH are among the leading companies in the Asia Pacific pharmaceutical fill and finish outsourcing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for pharmaceutical fill and finish outsourcing market is segmented into state of finished products and content. Based on state of finished products, the Asia Pacific pharmaceutical fill and finish outsourcing market is segmented into solids, semi-liquid and liquid. Based on content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. Geographically, the pharmaceutical fill and finish outsourcing market is segmented into Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com